Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 1)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Sponsor: Parexel
A PHASE2 clinical study on Chronic Plaque Psoriasis, this trial is completed. The trial is conducted by Parexel and has accumulated 17 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE2
▶ Show 12 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Nov 2019 — Dec 2020 [monthly]
Completed PHASE2
-
Sep 2018 — Nov 2019 [monthly]
Completed PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Parexel
- UCB Biopharma S.P.R.L.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Cleveland, United States , Dallas, United States , Edmonton, Canada , Fremont, United States , Gdansk, Poland , Gdynia, Poland , Hamilton, Canada , Houston, United States , Kecskemét, Hungary and 25 more locations